Latest Dilution News

S2 Resources has agreed to sell its Fosterville exploration licence to Agnico Eagle for A$17 million and raised an additional A$3 million through a strategic share placement, positioning the company strongly for future exploration.

Holista Colltech has raised $2.295 million through a share placement to two international investors, aiming to bolster its operations and balance sheet. The move highlights the company’s ongoing efforts to support growth across its health and wellness divisions.

Terramin Australia Limited has announced a pro-rata non-renounceable rights issue to raise approximately $38.3 million, partially underwritten by major shareholder Asipac Group Ltd. The capital raise aims to fund key project developments and repay debt, while potentially diluting existing shareholders and increasing Asipac’s voting power.

Terramin Australia has announced a $38.3 million non-renounceable rights issue to fund key project developments and reduce debt, offering shareholders shares at a 20% discount.

Revolver Resources has completed a key drilling program at its Dianne Copper Mine Project, affirming resource estimates and progressing towards a targeted production restart in late 2026. The company also secured significant funding to support upcoming development milestones.

Viridis Mining and Minerals has delivered a landmark Pre-Feasibility Study for its Colossus Rare Earth Project, confirming robust economics and securing key strategic funding and land expansions in Brazil.

Ark Mines secured a $4.5 million strategic investment from QIC to fast-track its Sandy Mitchell Rare Earth Project, achieving key drilling and environmental milestones that pave the way for production by late 2027.

Nelson Resources confirms high-grade gold assay results at its Yarri Project and partners with MEGA Resources to fully fund and manage development operations.

Omnia Metals Group has successfully issued 54 million shares, raising $1.08 million as part of a broader $1.58 million placement. The company now looks to shareholders for approval to complete the remaining share and option issues.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Star Minerals has raised $1.5 million through a share placement to fund critical drilling and mining approvals at its Tumblegum South Gold Project, aiming for production start in early 2026.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.